BIOMED CENTRAL

S. Gayathri MSFBI1506

1st M.sc Bioinformatics Bioinformatics Databases

BIOMED CENTRAL

Biomed central is united kingdom based, for profit scientific publisher specialising in open access journal publication.

Biomed central and its sister companies chemistry central and physmath central publish over 200 scientific journals.

Most biomed central describes itself as the first and largest open access science publisher.

Its is owned by Springer science + Business Media.

History of Biomed Central

Biomed central was founded in 2000 as part of the current science group

The first director of the company was Jan Vetterop.

In 2002, the company’s business model evolved to include article process charges.

In October 2008, it was announced that Biomed central had been acquired by spring science + Business media, the second largest STM publisher.

In 2007 Yale University libraries stopped subsiding page charges for affiliates of Yale whose using Biomed central as the publisher of their works.

In November 2008 Biomed central became an official supporting organization of Healthcare Information.

JOURNAL Biomed central owns and produces in house

five journals :i. Genome biologusii. Genome medicineiii. Arthritis Research and Therapyiv. Breast cancer Researchv. Critical care

• It also produces the BMC journal series of 65 journals covering the fields of biology and medicine.

• Chemistry central journal and Physmath series of journals are also produces by the company.

• Most of the other journals published by Biomed central are owned and produced independently by societies and academic editorial boards, with Biomed central providing the hosting publishing platform and marketing.

Home page

OPEN ACCESS

Open access publishing allows free distribution and access to published articles

The author retains copyright of their work a creative commons attribution licence.

So, all articles are made freely available to the widest audience possible.

Biology, medicine, health are the areas include in biomed central.

TIME FOR CHANGING Fifteen years ago, the business model for

scientific publishers was to charge users to view the articles they published.

This subscription based model for scientific publishers was to charge users to view the articles they published.

Biomed central open access publishing model changed all that.

THE BENEFITS :

The benefits are :o All articles are free to read, copy, distribute

and use(with attribution).

BIOMED CENTRAL THE FIRST OPEN ACCESS PUBLISHERS

Part of current science group Published first article in mid-2000 Strict policy of immediate open access

to all research article.

PLOS

Public Library of science : PLOS is a non-profit publisher and advocacy

organisation founded to accelerate progress in science and medicine by leading a transformation in research communication.

PEER-REVIWED ARTICLE

Peer- reviewed(refered or scholarly) journals. Articles are written by exports and are

reviewed by several other experts in the field before the article is published in the field before to insure the article’s quality.

PUBLISHED AND BE FREE In a landmark deal more than 80,000 biology and

medicine researches working at UK universities can now share their research finding freely with fellows researches post graduates students and the general public world wide.

The scheme covers 180 universities and colleges and researches in the NHS in England.

The biomed central membership agreement begins the article processing charges will be waived for all UK higher education staff when they published in any of Biomed central’s 90-plus peer reviewed journals in which all research content is freely accessible.

BIOMED CENTRAL JOURNALS ARE ARCHEIVED IN SEVERAL WAYS :

On the company’s own servers on Pubmed central’s serves, through CD- ROM collections developed by national libraries through the archive etc.,

Since the material is available without registration or subscription search engines such as Google also index much of the research material.

AIM AND SCOPE

Unreported or unusual side effects or adverse interaction involving medications.

Unexpected or unusual presentations of a disease

New associations or variations on disease process

Presentations, diagnoses and management of new and emerging diseases.

an unexpected association between diseases or symptoms.

Continue…

An unexpected event in the course of observing or treating a patients.

Findings that shed new light on the possible pathogenesis of a disease or an adverse effect.

Authors should indicate in the abstract and cover letter how the case report adds to the medical literature.

Submissions that do not indicate this information be returned to authors prior to peer review.